50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
NASDAQ:BCYC

Bicycle Therapeutics - BCYC Stock Forecast, Price & News

$22.92
-1.19 (-4.94%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$22.04
$24.38
50-Day Range
$19.60
$28.44
52-Week Range
$12.08
$62.08
Volume
191,303 shs
Average Volume
231,423 shs
Market Capitalization
$680.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.58

Bicycle Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
142.5% Upside
$55.58 Price Target
Short Interest
Bearish
9.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Bicycle Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.80) to ($4.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

598th out of 1,080 stocks

Pharmaceutical Preparations Industry

279th out of 535 stocks

BCYC stock logo

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

Bicycle Therapeutics (NASDAQ:BCYC) PT Lowered to $45.00
6 Analysts Have This to Say About Bicycle Therapeutics
Best Bike Rack for 2022
UA hosting Bicycle Safety Block Party
See More Headlines
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Company Calendar

Last Earnings
8/04/2022
Today
9/24/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCYC
Fax
N/A
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.58
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+142.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

Net Income
$-66,820,000.00
Net Margins
-533.03%
Pretax Margin
-545.44%

Debt

Sales & Book Value

Annual Sales
$11.70 million
Book Value
$11.78 per share

Miscellaneous

Free Float
27,005,000
Market Cap
$680.27 million
Optionable
Not Optionable
Beta
0.71

Key Executives

  • Dr. Kevin Lee M.B.A. (Age 53)
    Ph.D., CEO & Exec. Director
    Comp: $1.4M
  • Mr. Lee H. Kalowski M.B.A. (Age 41)
    MBA, Pres & CFO
    Comp: $832.36k
  • Sir Gregory Paul Winter CBE (Age 71)
    FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board
    Comp: $40k
  • Dr. Michael Skynner B.sc. Ph.d. (Age 52)
    Ph.D., Chief Technology Officer
    Comp: $925.3k
  • Dr. Christian Heinis
    Scientific Founder
  • Mr. Alistair Milnes
    Chief Operating Officer
  • Dr. Nicholas Keen Ph.D. (Age 54)
    Chief Scientific Officer
  • Mr. David E. Borah CFA
    VP of Capital Markets & Investor Relations
  • Mr. Zafar Qadir
    Gen. Counsel
  • Dr. Gillian Langford
    Head of Clinical and Project Management













BCYC Stock - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings
or view top-rated stocks.

What is Bicycle Therapeutics' stock price forecast for 2022?

14 equities research analysts have issued 12 month target prices for Bicycle Therapeutics' shares. Their BCYC share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's stock price to reach $55.58 in the next twelve months. This suggests a possible upside of 142.5% from the stock's current price.
View analysts price targets for BCYC
or view top-rated stocks among Wall Street analysts.

How have BCYC shares performed in 2022?

Bicycle Therapeutics' stock was trading at $60.87 at the beginning of 2022. Since then, BCYC shares have decreased by 62.3% and is now trading at $22.92.
View the best growth stocks for 2022 here
.

When is Bicycle Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our BCYC earnings forecast
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) issued its earnings results on Thursday, August, 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.05. Bicycle Therapeutics had a negative net margin of 533.03% and a negative trailing twelve-month return on equity of 30.07%.

What other stocks do shareholders of Bicycle Therapeutics own?
When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (4.87%), Samlyn Capital LLC (3.51%), SV Health Investors LLC (3.06%), Candriam S.C.A. (2.82%), FMR LLC (2.39%) and First Light Asset Management LLC (2.37%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends
.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $22.92.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $680.27 million and generates $11.70 million in revenue each year. The company earns $-66,820,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

The company employs 119 workers across the globe.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503.

This page (NASDAQ:BCYC) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.